THE PRIMARY CARE COMPANION
FOR CNS DISORDERS

Supplementary Material

Article Title:

Resource Utilization and Costs Associated With Insomnia Treatment in Patients With Major Depressive Disorder

Author(s):   Haijun Tian, PhD; Safiya Abouzaid, PharmD; Susan Gabriel, MSc; Kristijan H. Kahler, PhD, RPh; and Edward Kim, MD, MBA

List of Supplementary Material for the article

1. Appendix 1   Antidepressant and Insomnia Medications

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Appendix 1. Antidepressant and Insomnia Medications

Antidepressant Medications

Amitriptyline hydrochloride

Amoxapine

Bupropion hydrobromide

Citalopram hydrobromide

Clomipramine hydrochloride

Desipramine hydrochloride

Desvenlafaxine succinate

Doxepin hydrochloride

Duloxetine hydrochloride

Escitalopram oxalate

Fluoxetine hydrochloride

Fluvoxamine maleate

Imipramine hydrochloride

Isocarboxazid

Maprotiline hydrochloride

Mirtazapine

Nefazodone hydrochloride

Nortriptyline hydrochloride

Paroxetine hydrochloride

Phenelzine sulfate

Protriptyline hydrochloride

Selegiline

Sertraline hydrochloride

Tranylcypromine sulfate

Trazodone hydrochloride

Trimipramine maleate

Venlafaxine hydrochloride

Insomnia Medications[a]

Ambien, Ambien CR (zolpidem tartrate)

Butisol sodium

Carbrital (pentobarbital and carbromal)

Dalmane (flurazepam hydrochloride)

Doral (quazepam)

Halcion (triazolam)

Lunesta (eszopiclone)

Placidyl (ethchlorvynol)

Prosom (estazolam)

Restoril (temazepam)

Rozerem (ramelteon)

Seconal (secobarbital sodium)

Sonata (zaleplon)

[a]Based on US Food and Drug Administration. Drugs: Sleep Disorder (Sedative-Hypnotic) Drug Information. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm101557.htm. Accessed July 25, 2012.